Indication: Migraine - prevention
RAG rating: Red
Document type: NICE technology appraisal
Place: Hertfordshire and West Essex ICB
Output type: Pharmacy / Prescribing

Atogepant

NICE Technology Appraisal 973recommends atogepant as an option for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventive medicines have failed.

Atogepant should be stopped after 12 weeks if the frequency of migraines does not reduce by:

at least 50% in episodic migraine (defined as fewer than 15 headache days per month)
at least 30% in chronic migraine (defined as 15 or more headache days per month, with at least 8 of those having features of migraine).

Atogepant is has been assigned an interim RED RAG rating with a view to moving to AMBER INITIATION pendingthe development and approval of new migraine pathways and primary care prescribing support documents with specialist and primary care prescribers.

Any update to local guidelines will be published on the Hertfordshire and West Essex ICB Prescribing, Policies and Pathways website at https://www.hweclinicalguidance.nhs.uk/home.

Back